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Background: Smoking is the main preventable cause of morbidity and mortality in our region, it being the main
causative agent of chronic obstructive pulmonary disease. There still is no consensus on the use of spirometry as a
strategy for smoking cessation, given that there is insufficient scientific evidence from high quality studies to
recommend the use of this technique.
Methods/Design: This is to be a randomized, multicentre, open-label clinical trial. A total of 444 smokers over
40 years of age will be recruited by 39 general practitioners from 22 health centers. Primary objective of this study
is to assess the effectiveness of spirometry together with information regarding the test for smoking cessation after
1 year in smokers over 40 years of age with a more than 10 pack-year history and no previous diagnosis of chronic
obstructive pulmonary disease. Groups of 45 patients who smoke will be randomly selected from the lists of the
participating doctors. The names will be sent to the corresponding doctors who will contact candidate patients and
assess whether they meet the selection criteria. Patients who meet these criteria will be randomly allocated to an
intervention or control group. For patients in both groups, a nurse will conduct an interview and perform a
spirometry test to measure forced vital capacity. Then, all patients will be referred for an appointment with their
doctor for brief anti-smoking intervention, patients from the intervention group additionally being informed about
the result of the spirometry test. After 1 year, smoking status will be assessed and, in those who report that they
have quit smoking, abstinence will be confirmed by co-oximetry. Data will be analyzed on an intention-to-treat
basis using the chi-squared test for outcomes and binary logistic regression if it is considered to be necessary to
adjust for confounding variables.
Discussion: Performing a spirometry test and providing information on pulmonary function may increase
awareness of the effect of smoking among smokers who are asymptomatic or have few symptoms and make them
decide to quit. Specifically, in patients with chronic obstructive pulmonary disease it might increase levels of
motivation to quit smoking in early stages of the disease. If this strategy were to be effective, it could be included
in the health promotion activities offered in primary care.
Trial registration: ClinicalTrials.gov Identifier: NCT01821885
Keywords: Spirometry, Screening, Smoking, COPD* Correspondence: MARIAISABEL.IRIZARARAMBURU@osakidetza.net
1Idiazabal Primary Care Medical Centre, Idiazabal, Gipuzkoa, Spain
Full list of author information is available at the end of the article
© 2013 Irizar-Aramburu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Irizar-Aramburu et al. BMC Family Practice 2013, 14:185 Page 2 of 8
http://www.biomedcentral.com/1471-2296/14/185Background
Smoking is the main cause of preventable mortality and
morbidity in industrialized countries. It is estimated that
in Spain, as many as 56,000 people die every year due to
smoking [1]. It is one of the main risk factors for vascular
and respiratory diseases and a causative agent for chronic
obstructive pulmonary disease (COPD), accelerating the
physiological worsening of the lung volume in susceptible
smokers [2,3]. COPD is a disease with a high prevalence
(10.2% in 40- to 80-year-olds) and a high rate of under-
diagnosis (72% of those with COPD not having been
diagnosed), according to the EPISCAN study [4]. It is
the fifth cause of death in Spain and one of the main
causes of morbidity, responsible for a profound worsening
in quality of life, especially in advanced stages of the disease
[5]. The World Health Organization (WHO) predicts
that by 2030, COPD will go from 12th to 5th place in the
list of most prevalent diseases in the world, and from 6th
to 3rd place in terms of mortality [6]. These data justify
the Spanish National Health System launching a strat-
egy against COPD in 2009 [7] focused around smoking
cessation interventions.
Smoking is the main cause of COPD, being associated
with more than 80% of cases. According to a study by
Fletcher et al. [2], 15 to 20% of smokers develop COPD,
more recent studies [8,9] arguing that the figure may in
fact be as high as 50%. After the results of the Lung Health
Study [10] in 1994, a randomized clinical trial that dem-
onstrated that an intensive anti-smoking intervention in
patients with mild and moderate COPD managed to
halt the decline in FEV1, several consensus statements
have recommended spirometry testing in smokers to bene-
fit their general health. In 2000, one of the main sponsors
of the screening programs for COPD was the American
National Lung Health Education Program (NLHEP) [11]
who advocated the use of spirometry for COPD screening
in all patients with any respiratory signs and in smokers
aged over 45 years old. COPD meets some of the criteria
proposed by Frame and Carlson [12] to justify a screening
program, that is, it is an important health problem with
an long initial asymptomatic stage; there is a screening test
with high sensitivity and specificity, namely spirometry,
which is considered the gold standard for the diagnosis;
and there is a treatment that, if administered in the
asymptomatic stage, is effective in reducing overall mor-
bidity and mortality, in this case smoking cessation [2].
Any screening test must have a good cost-effectiveness
ratio. The cost-effectiveness of spirometry depends on
various factors, such as the number of patients that need
to be screened to detect one case of COPD or, better, to
result in one person stopping smoking. In the Lung Health
Study [10], the most significant results were obtained in
middle-aged patients (mean age of 48 years), with mild or
moderate COPD (mean post-bronchodilator FEV1 of 78%),most of whom did not consider themselves “ill”: patients
from the anti-smoking intervention group had a smaller
decrease in FEV1, the authors concluding that spirometry is
cost-effective since it permits the early detection of COPD
and focusing measures on these patients. Other authors
[13] concluded that even modest quit rates attributable
to spirometry may be cost-effective, although the authors
comment that further studies are required to assess the in-
dependent role of spirometry in smoking cessation.
Later, in 2005, the American Agency for Healthcare
Research and Quality (AHRQ) published a systematic
review [14] concluding that the benefits of spirometry
for opportunistic screening to detect COPD in smokers
and ex-smokers will remain unclear until it is demonstrated
that spirometry contributes to increasing the number
of patients who quit smoking. This review included
seven clinical trials of which only one [15] assessed the
independent contribution of spirometry in smokers
and, though they found the quit rate was higher among
those who underwent spirometry as well as receiving
advice (6.5 vs. 5.5% in those who only received advice),
the difference was not significant. The authors of this
review also indicated the need for further studies to de-
termine the role of spirometry in smoking cessation.
Another systematic review, that of the U.S. Preventive
Services Task Force (USPTF) published in 2008 [16], a
subsequent systematic review [17] and a 2005 Cochrane
review, on the efficacy of assessing biomedical risks
(among them pulmonary function) as a tool for quitting
smoking [18], all concluded that the evidence of a role
of spirometry as a motivational tool to encourage smok-
ing cessation is inconclusive, as most studies had a short
follow-up period and significant limitations, such as not
assessing the independent role of spirometry and insuf-
ficiently large sample sizes.
A 2012 updated review of the Cochrane Collaboration
[19] found little scientific evidence of an effect on quitting
smoking for most biomedical tests. Out of the 15 studies
included, only 2 of them detected a significant effect: a
trial based on ultrasound of carotid and femoral arteries
and another on spirometry combined with information
on test results in terms of “lung age” [20] which found a
significant improvement in the smoking cessation success
rate compared to the control group that did not receive
the spirometry test report (RR 2.12; CI 95% 1.24 to 3.62).
Nevertheless, this study still did not assess the independent
role of spirometry, as testing was used in both the ex-
perimental and control groups.
Based on the available evidence, the executive summary
of the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) published in 2013 [21], the international
reference, the guidelines of the Spanish Society of Family
and Community Medicine and the Spanish Society of
Pulmonology and Thoracic Surgery (semFYC-SEPAR)
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[23] advocate “opportunistic” case finding by spirometry
only in smokers with respiratory symptoms. However,
there is no consensus on this strategy in the scientific
community, some authors questioning the usefulness of
COPD screening in asymptomatic smokers due to the
weak correlation between these symptoms in smokers
and COPD. A cohort study [24], including 3,955 people in
the USA recruited between 1980 and 2008, that attempted
to assess the association between respiratory symptoms
and airflow obstruction, confirmed the under-diagnosis of
airway obstruction in smokers and concluded that respira-
tory symptoms have low sensitivity, specificity, and positive
and negative predictive values for diagnosing COPD, given
that these symptoms are common in smokers with and
without airway obstruction; on this basis, the authors advo-
cate spirometry testing in all smokers older than 40 years of
age with a more than 20 pack-year history of smoking with
or without respiratory symptoms.
Therefore, given the available evidence and the lack of
high quality clinical trials assessing the independent role
of spirometry in smoking cessation, and that discovering
they have COPD may help people quit smoking, we believe
that the study we propose may be useful to clarify various
issues. Specifically, if our hypothesis were to be correct and
spirometry testing did help people quit smoking, public
health authorities would have a basis on which to promote
this strategy, as it would have the potential to change life-
styles and thereby prevent highly prevalent medical condi-
tions such as various types of cancer and cardiovascular
disorders, as well as COPD. Additionally, if a significantly
higher rate of smokers with an early diagnosis of COPD
quit smoking than those with no diagnosis of airway ob-
struction, the demonstrated beneficial effect in terms of
reducing morbidity and mortality due to COPD, would
in itself justify the screening. If, on the other hand, no
significant effect on smoking cessation were detected,
there would be no arguments supporting COPD screening
by spirometry, and we should probably stop performing
spirometry tests for this purpose, thus avoiding an un-
necessary use of resources. The protocol we present
here aims to provide evidence to address this issue, by
attempting to determine whether conducting spirometry
testing to screen for COPD and informing individuals about
their results is effective in encouraging smoking cessation
in smokers older than 40 years of age with a more than
10 pack-year history.
Objectives
The primary objective of this study is to assess the ef-
fectiveness of spirometry testing together with providing
patients with information about their results for smoking
cessation after 1 year in people older than 40 years of
age with a more than 10 pack-year history who have notbeen diagnosed with COPD (at the outset of the study). The
secondary objectives include comparing the quit rates in pa-
tients with a new diagnosis of COPD and those with normal
lung function, and comparing the change in daily smoking
rate between the intervention and control groups.
Methods/Design
This is a multicentre, open-label, randomized clinical trial.
Study subjects are active smokers older than 40 years of
age with a more than 10 pack-year history who have not
been diagnosed with COPD, from 39 general practitioner
(GP) lists within the province of Gipuzkoa. The follow-
ing patients will be excluded: any who are older than
80 years of age or institutionalized, as well as any who
have a life expectancy of less than 1 year, have under-
gone spirometry testing within the previous 2 years,
have been previously diagnosed with respiratory diseases
(asthma, interstitial lung diseases, or COPD) that cause pat-
tern changes in spirometry tests, or have contraindications
for spirometry testing (Table 1). This clinical trial has been
registered in ClinicalTrials.gov (NCT01821885).
A sample of 444 people will be recruited. The sample
size calculation was based on assuming a level of signifi-
cance of 5%, a quit rate after brief anti-smoking interven-
tion only (control group) of 5% [23], an expected quit rate
in the experimental group of 14% [20], and a 1:1 ratio of
control to experimental subjects. Given these premises, to
obtain a power of 80% to detect differences in the test of
the null hypothesis Ho: p1 = p2 using a two-tailed chi-
squared test for two independent samples, it would be
necessary to include 166 experimental units in the refer-
ence group and a further 166 in the experimental group,
making a total of 332 units for the study. Assuming a
loss to follow-up of 25%, it would be necessary to recruit
222 subjects for the reference group and a further 222 for
the experimental group, summing to the aforementioned
total of 444 subjects for the study. The flow chart for the
study is presented in Figure 1.
Recruitment and randomization
A total of 39 doctors from a research group of an Osakidetza
health region within Gipuzkoa are participating in the
study. These 39 health professionals work in 22 health
centers covering both rural areas (25% of the GP lists)
and urban areas, with populations of over 10,000 people
(75% of the GP lists).
The total catchment population of these 39 doctors is
58,540 people over 14 years of age. Primary care elec-
tronic medical records will be used to identify a sample
of these patients who smoke: we will randomly select
subjects from the GP lists obtaining a sample of 1775
patients (45 patients per doctor) and each doctor will be
informed of the patients in his/her list selected as candi-
dates for the study. After this, the participating doctors
Table 1 Definition of the study variables
Active smoker Diagnosis of chronic obstructive pulmonary disease (COPD)
Any patient who smokes one or more cigarettes per day will be considered
an active smoker.
The criteria for the diagnosis of COPD is a post-bronchodilator
FEV1/FVC ratio of < 70% (absolute value).
Spirometry technique Spirometric patterns
Baseline spirometry: the nurse responsible for the spirometry testing will
be experienced in the technique and familiar with the ATS/ERS criteria for
acceptability (correct start with back extrapolated volume of <150 ml or 5%,
curve with no marks or notches and correct end, with no leaks and lasting
at least 6 seconds or with a plateau > 1 second in the volume-time curve).
Spirometry results will be considered within the normal range if
FEV1/FVC > 70% (absolute value) and FVC and FEV1 > 80% of the
predicted values.
The pattern is classified as obstructive if FEV1/FVC < 70% (absolute value).
To meet the criteria for repeatability, there must be three acceptable
manoeuvres and the FVC and FEV1 values in the two best two must
differ by no more than 100 ml.
The pattern is classified as restrictive if FEV1/FVC > 70% (absolute value)
and FVC < 80% of the predicted value.
The pattern is classified as mixed if FEV1/FVC < 70% (absolute value)
and FVC < 80% of the predicted value.
Bronchial challenge: After performing the baseline test, patients will be
given 400 mcg of Salbutamol (in a holding chamber) and 15–20 minutes
later a further spirometry test will be conducted applying the same criteria
for acceptability and reproducibility as for the baseline test.
The bronchial challenge is regarded as positive when FEV1 or FVC
increase by 12% or 200 ml compared to baseline values 15–20 minutes
after administering 400 mcg of Salbutamol (in a holding chamber).
Contraindications for spirometry testing Quitting smoking
• Poor general health, old age, etc. A year after the intervention, patients will be considered to have
stopped smoking if they report abstinence (defined as no of
consumption of tobacco for at least 7 days) and this is confirmed by
CO-oximetry (a carbon monoxide concentration in exhaled air
of < 10 ppm is considered sufficient).
• Recent pneumothorax (< 6 months)
• Unstable angina or recent acute myocardial infarction (< 6 months)
• Recent retinal detachment (< 6 months)
• Recent abdominal or thoracic surgery (< 6 months) Co-oximetry technique
• Recent eye surgery (< 6 months) The patient takes a deep breath and holds it for 15 seconds. They
then breathe out slowly and completely (as far as they can). It is then
necessary to wait for several seconds until the CO-oximeter settles
and shows the exact concentration of carbon monoxide (CO) in parts
per million (ppm) in the air exhaled by the patient.
• Thoracic aortic aneurysm
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participating and contact eligible patients by phone to
obtain verbal informed consent to their participation in
the study and collect preliminary data. Patients will be re-
cruited in a pre-established order from the list provided
and the reasons for patient exclusion will be recorded on
an individual basis. Doctors will send data on the pa-
tients recruited to the Primary Care Research Unit of
the Gipuzkoa Health Region where the patients will be
randomly assigned to the intervention or control group.
The randomization sequence will be generated by com-
puter and kept in the research unit. The list of patients
assigned to each group will be sent to the nurses in charge
of the first appointment. At this appointment, once written
informed consent has been given, the interventions detailed
below will be performed for each group.
Intervention
Experimental group
The intervention consists of the nurse collecting data,
performing a spirometry test and then giving the patient
an appointment with their GP within 10 days. At thisappointment, the doctor will deliver a brief anti-smoking
intervention and provide the patient with a short explan-
ation of the spirometry results. Both the delivery of the
advice and the spirometry report will be carried out in a
standardised way (in accordance with the guidelines).
Control group
The nurse will only interview the patient to collect data
on the study variables and make them an appointment
with their GP within 10 days. The doctor will just perform
the brief anti-smoking intervention in the same standar-
dised way as for the intervention group. These patients will
not undergo spirometry during the study period of 1 year.
Nurses selected will have the skills and experience
necessary for performing spirometry. After finishing
this first phase of the study, two doctors with extensive
experience in interpreting spirometry will assessed test
results and exclude from further analysis any patients
whose results do not comply with the criteria for accept-
ability and repeatability of the American Thoracic Society/
European Respiratory Society (ATS/ERS). The nurses
involved will not deliver any intervention for smoking
Sample of 1,775 patients
Study sample
Any patients who decline to participate or do not meet 
the selection criteria are excluded
NURSE: interview + spirometry
GP: brief anti-smoking intervention + 
spirometry report
Patients 40 to 80 years old with a smoking habit recorded in 
primary care electronic medical records of 39 GP lists 
(excluding those with asthma or known chronic obstructive 
pulmonary disease [COPD])
Randomisation
EXPERIMENTAL GROUP CONTROL GROUP
Quit rate
in the experimental group
Quit rate











GP: brief anti-smoking intervention
Randomisation by GP list
Daily smoking rate
in the experimental group
Population: 58,540 (39 general practitioner [GP] lists)
Daily smoking rate
in the control group
Figure 1 Study flow chart.
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conduct the interviews and carry out the spirometry, avoid-
ing making any comments on the test results or any other
issues related to the patient’s health or smoking habit.
The research doctors will receive training in the study
protocol, including how to deliver the brief anti-smoking
intervention and report the results of the spirometry test,
and will receive a manual with written instructions,
summarized in Table 2. In order to avoid variability attrib-
utable to the use of different measurement devices, the
same models of spirometer (Datospir 120-C) and carbonmonoxide detector (Dräger Pac 7000 CO) will be used for
all the measurements.
Follow-up and assessment of results
All patients will be contacted by telephone 1 and 3 months
after the intervention to determine whether they have
stopped smoking and, if they have not, how many cigarettes
they are smoking per day at the time. One year after the
intervention a further phone call will be made by health
professionals blinded to the group allocation to assess the
patient’s smoking status. For patients that claim to have
Table 2 Intervention by the doctor – instruction manual (summary)
Brief anti-smoking intervention Information on the spirometry results
This will consist of a maximum 3 minutes of advice in which the health
professional explains clearly to the smoker that the most effective step
they could take to improve their health would be to stop smoking and
provides them background information in writing. The same material
will be provided to all patients and consists of two leaflets on the
benefits of stopping smoking (the leaflets being those provided by the
Department of Health of the Basque Government and routinely used
in primary care consultations for brief anti-smoking interventions).
In the event of spirometry detecting airway obstruction
(post-bronchodilator FEV1/FVC < 70%), the patient will be told that
they have chronic obstructive pulmonary disease secondary to
smoking and that it is very important that they stop their habit.
In the event of spirometry values being within the normal range,
the patient will be told that their respiratory function is not yet
impaired and that it would be a good moment to give up smoking.
In the event of a restrictive spirometry pattern, the patient will be
told that they have impaired pulmonary function and they will be
provided usual care.
In all cases, the doctor should address any concerns or queries of
the patient concerning the spirometry or any other issues that
arise during the consultation.
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confirm this using a CO-oximeter that measures the
carbon monoxide concentration in exhaled air.
Study variables
The primary outcome variable will be smoking cessation
1 year after the intervention, as reported by the patient and
confirmed by measuring exhaled CO, while the secondary
outcome variable will be the number of cigarettes/day
for those who continue smoking. Other variables to be
assessed include age, sex, body weight and height, BMI,
pack-year history, Prochaska’s stage of change, Richmond
test score, number of previous attempts to quit smoking,
number of periods of abstinence of more than 1 month,
use of medication for smoking cessation, respiratory
symptoms (coughing, expectoration, degree of dyspnoea),
comorbidities (high blood pressure, ischaemic heart
disease, cerebrovascular accident, peripheral arterial
disease, diabetes), and other habits (alcohol abuse, sedentary
lifestyle), as well as spirometry parameters (pre- and post-
bronchodilator FVC, FEV1, and FEV1/FVC ratio, predicted
FEV1/FVC%). The final outcome measures are to be:
CO-oximetry results (in patients who report having
stopped smoking), attempts to quit smoking in the previous
year, spirometry tests in previous years (excluding that of
the study), consultations related to smoking in the previous
year (excluding any related to the study), use of medication
for smoking cessation in the previous year, use of other
methods for smoking cessation in the previous year,
and quit rates at 1 and 3 months among those who
continue smoking.
Table 1 lists the definitions of the study variables.
Statistical analysis
Data will be analyzed on an intention-to-treat basis using
SPSS 19.0 software. Given that the primary outcome
measure is categorical in nature (whether patients do
or do not quit smoking), the final comparison will be
performed using chi-squared tests and effect size estimateswill be expressed as relative risk (RR), absolute risk reduc-
tion (ARR), and number needed to treat (NNT) with the
corresponding 95% confidence interval (95% CI). Continu-
ous variables will be assessed with the Student’s t-test, if the
data meet the assumption of normality, and otherwise with
the corresponding non-parametric test.
If this initial analysis demonstrates the need for multi-
variate analysis, binary logistic regression analysis will be
used. This type of model will allow us to compare the
primary outcome measure between groups adjusting for
any observed differences, and thus minimizing the po-
tential for confounding bias in the final comparison
between intervention and control groups. In this case,
all the estimations would be expressed as odds ratios
with 95% confidence intervals.
Limitations
Since we will be using an electronic medical record
database, any under-recording of smoking habits would
mean that some smokers would be excluded from the
study. However, according to our internal data, patients’
smoking habits are relatively reliably documented in
their primary care medical record. Further, given the
type of intervention that will be undertaken, it is not
possible to use double blind study design (that would be
with blinding of patients and doctors). In order to overcome
this, doctors and nurses participating in the study will
receive special training, so that the messages they give
and their attitudes and behaviors are similar with the
two groups (except with regards to delivering the inter-
vention under study), while the second nurse who will
assess the smoking status after one year and the person
analyzing the results will be blinded to the group alloca-
tion of the patients.
Ethical considerations
The study protocol and informed consent forms were
submitted to the Clinical Research Ethics Committee of
the Gipuzkoa Health Region and approved, as recorded
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that the study is conducted in compliance with the prin-
ciples of the Declaration of Helsinki and the ICH guide-
lines for good clinical practice and applicable legislation.
All the participants will be informed about the study,
its objectives and activities related to their participation,
the number of visits, tests to be performed, information
on the results, etc. They will be also informed that in the
event of any health problem being detected in the course
of the study, they will be treated as usual, if necessary
being referred to an appropriate unit for diagnosis and
treatment, to ensure that they receive the best treatment
for their condition. The aforementioned types of informa-
tion will be provided in writing and individuals will be
asked to sign an informed consent form prior inclusion.
Discussion
The role of primary care in the early diagnosis of COPD
is indisputable, as is the need for spirometry testing to
diagnose this condition [25]. This technique is currently
well established in primary care consultations, the quality
of the tests having greatly improved in this level of care
[24]. On the other hand, the early diagnosis of COPD by
spirometry is still somewhat controversial. Assuming that
most of the diagnoses would be mild or moderate COPD,
the most important measure to improve morbidity and
mortality would be smoking cessation and, as we have
noted, very few high quality studies have assessed the
independent role of spirometry for achieving this objective
[14,16]. Of all the studies identified, only two investigated
the independent role of spirometry for smoking cessation
and both reached negative conclusions [15,26]. More re-
cently, in 2008, Parkes et al. [20] found that by presenting
spirometry results in terms of “lung age” there was a
greater decrease in smoking than in a control group who
were presented the results in the usual way. Nevertheless,
this study does not fully clarify the role of spirometry as
testing was performed for both groups. Some previous ob-
servational studies [27,28] have found higher quit rates in
patients diagnosed with COPD. On the other hand, in
order to achieve good results in COPD screening, the in-
crease in quit rates would need go beyond the patients
with a new diagnosis of COPD, and extend to smokers in
general; this is because if there were higher quit rates in
COPD patients without a parallel increase across all the
smokers analyzed, the intervention would lose some of its
value, since we could assume that the absence of effective-
ness were due to the potential reassuring effect for many
smokers of discovering that they have “normal” lung func-
tion. For this reason, the primary objective of our study is
to assess whether performing spirometry and informing
patients of the results increases the quit rate in smokers
over 40 years of age with a smoking history of more than 10
pack-years, whether they have COPD or not, the secondaryobjectives being to achieve smoking cessation in those with
COPD and decrease the consumption of cigarettes in those
who continue to smoke.
Some ethical considerations have been raised about
the potential harm of screening labeling patients with
the diagnosis of COPD. In a study focusing on this issue
[29], 86% of smokers agreed with lung function being
measured since this could increase awareness of the
negative effects of smoking and increase motivation to
give up smoking.
Another potential issue concerns the cost-effectiveness
of COPD screening, namely whether it may more effective
to carry out spirometry tests on smokers with symptoms
as recommended by guidelines [21-23], or on the basis of
the number of pack-years smoked. Although, in any case,
the objective is to achieve smoking cessation, a change of
strategy could be considered depending on the findings of
our study, given that other research [30] has demonstrated
that the risk of COPD is positively associated with the
cumulative smoking index and, on the other hand, there
is direct relationship between the intensity of smoking
and general morbidity and mortality [31]. As well as the
specific objectives of the study, its findings may contribute
to determining the percentage of patients who smoke
who in fact have COPD, the severity of their condition,
and whether the risk of having COPD is greater in pa-
tients with symptoms or whether it is more closely related
to pack-year history.
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